Latest Breaking News On - Mark lanasa - Page 10 : comparemela.com

Tislelizumab is now approved in seven indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative

United statesLin shenKevin mannixEmily collinsMark lanasaXiaobin wuNational cancer instituteDrug administrationBeigene ltdExchange commissionAmerican society of clinical oncology annual meetingTislelizumab clinical programChina national medical products administrationBristol myers squibbSenior vice presidentChief medical officer